AKTIS ONCOLOGY INC (AKTS) Stock Analyst Ratings

NASDAQ:AKTS • US01021M1045

20 USD
-0.13 (-0.65%)
At close: Mar 2, 2026
20 USD
0 (0%)
After Hours: 3/2/2026, 8:01:58 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Buy % Consensus

46

ChartMill assigns a Buy % Consensus number of 46% to AKTS. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 33.15. This target is 65.75% above the current price.
  • AKTS was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about AKTS.
  • In the last month the buy percentage fell by 32 points. So the trust of analysts is decreasing.
  • AKTS was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

Find peers with buy consensus above 85%
AKTS Historical Analyst RatingsAKTS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 20.0031.3133.1533.1535.70 - 56.55% 65.75% 65.75% 78.50%

Related screens

Find peers 30% below price target
AKTS Current Analyst RatingAKTS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2026-02-03 Leerink Partners Initiate Outperform
2026-02-03 JP Morgan Initiate Overweight
2024-01-04 Piper Sandler Downgrade Overweight -> Neutral
2023-09-07 Oppenheimer Maintains Outperform -> Outperform
2023-09-07 B. Riley Securities Downgrade Buy -> Neutral
2023-05-09 Roth MKM Maintains Buy
2023-05-09 Oppenheimer Maintains Outperform
2023-01-24 B. Riley Securities Initiate Buy
2022-11-15 Oppenheimer Maintains Outperform
2022-09-13 Piper Sandler Maintains Overweight
2022-05-03 Piper Sandler Maintains Overweight
2021-11-02 Oppenheimer Maintains Outperform
2021-05-04 Roth Capital Maintains Buy

AKTIS ONCOLOGY INC / AKTS FAQ

What is the average price target for AKTIS ONCOLOGY INC (AKTS) stock?

7 analysts have analysed AKTS and the average price target is 33.15 USD. This implies a price increase of 65.75% is expected in the next year compared to the current price of 20.


What is the consensus rating for AKTS stock?

The consensus rating for AKTIS ONCOLOGY INC (AKTS) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.